# Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants

> **NCT07673900** · PHASE1 · RECRUITING · sponsor: **Terrestrial Bio, Inc.** · enrollment: 62 (estimated)

## Conditions studied

- Overweight and/or Obesity

## Interventions

- **COMBINATION_PRODUCT:** VX-201
- **DRUG:** semaglutide SC

## Key facts

- **NCT ID:** NCT07673900
- **Lead sponsor:** Terrestrial Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2027-02-10
- **Final completion:** 2027-05-18
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2026-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07673900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07673900, "Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07673900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*